| Schedule of Related Party Transactions |
The table below provides a summary of
activity between the Company and Pharma and NDM for the six months ended September 30, 2020 and 2019, and the year ended March
31, 2020. These amounts are unsecured, interest free, and payable on demand.
| |
|
|
Six Months Ended September 30, 2020
(unaudited)
($) |
|
|
|
Six Months Ended September 30, 2019
(unaudited)
($) |
|
|
|
Year Ended March 31, 2020
($) |
|
| Liability due to related parties at beginning of period |
|
|
830,093 |
|
|
|
964,679 |
|
|
|
964,679 |
|
| Amounts invoiced by Pharma to DDL, NM and TCL (1) |
|
|
698,300 |
|
|
|
966,425 |
|
|
|
1,800,517 |
|
| Amounts invoiced by DDL to Pharma |
|
|
(7,060 |
) |
|
|
(814 |
) |
|
|
(10,963 |
) |
| Amounts paid by DDL to Pharma |
|
|
(1,388,874 |
) |
|
|
(867,013 |
) |
|
|
(1,897,222 |
) |
| Foreign exchange differences |
|
|
21,074 |
|
|
|
(56,743 |
) |
|
|
(26,918 |
) |
| Liability due to related parties at end of period |
|
|
153,533 |
|
|
|
1,006,534 |
|
|
|
830,093 |
|
| |
(1) |
These amounts are included primarily in research and development expenses charged to the Company by Pharma. |
|